PODO447-Vedotin

PODO447-Vedotin is an antibody-drug conjugate (ADC) designed to target a tumor-restricted glycoepitope on the extracellular mucin domain of podocalyxin (Podxl). Podocalyxin is a cell surface sialomucin frequently upregulated in tumors with high metastatic potential, and its expression is associated with poor outcomes in several human cancers. The ADC consists of the PODO447 monoclonal antibody, which selectively recognizes the tumor glycoform of Podxl while sparing normal tissues (such as vascular endothelia and kidney podocytes), conjugated to the microtubule-disrupting payload monomethyl auristatin E (MMAE) via an enzyme-cleavable carbamoyl p-aminobenzyl carbamate (PABC) linker. Developed by researchers at the University of British Columbia, PODO447-Vedotin has demonstrated promising in vitro activity and in vivo efficacy in xenograft models of ovarian and pancreatic tumors, as well as binding to a wide range of other solid tumors including breast, lung, and glioblastoma.

Other names

PODO447-MMAEPODO-447-MMAEPODO 447-MMAE